title: Decade in review--heart failure: 10 Years of progress in HF research--what have we learned?
abstract: In this Decade in Review article, I highlight the top 10 advances in heart failure (HF) over the past decade, including new pharmacological therapies and expanded indications for devices in HF with reduced ejection fraction.The poor progress in acute HF and HF with preserved ejection fraction is emphasised. Biomarkers and devices that help prevent, detect, and guide treatment represent the future of HF management.
authors.affiliation: Centre of Cardiovascular Research &Education in Therapeutics, School of Public Health &Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, VIC 3004, Australia.
authors.forename: Henry
authors.initials: H
authors.lastname: Krum
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D058406:Cardiac Resynchronization Therapy; D015316:Genetic Therapy; D006333:Heart Failure / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D013318:Stroke Volume
chemical_list: D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D000451:Mineralocorticoid Receptor Antagonists